Calcitonin screening and pentagastrin testing: Predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease

European Journal of Endocrinology

Volumn 162, Issue 6, 2010, Pages 1141-1145

  Herrmann, B L ^a,b   Schmid, K W ^a   Goerges, R ^a   Kemen, M ^c   Mann, K ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Division of Endocrinology Diabetology and Laboratory   (Germany)

^c Ev Hospital Herne   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PENTAGASTRIN;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER SCREENING; CANCER SURGERY; CANCER TISSUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROVOCATION TEST; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID SURGERY;

ADULT; AGED; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTAGASTRIN; PREDICTIVE VALUE OF TESTS; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 77949282406     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0111     Document Type: Article

References (35)

1. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R & Schumm-Draeger PM. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 2004 14 926-932. (Pubitemid 39612911)
2. Raue F, Zink A & Scherubl H. Regulation of calcitonin secretion and calcitonin gene expression. Recent Results in Cancer Research 1992 125 1-18.
3. Santoro M, Melillo RM, Carlomagno F, Vecchio G & Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004 145 5448-5451. (Pubitemid 39564582)
4. Hegedus L. Clinical practice. The thyroid nodule. New England Journal of Medicine 2004 351 1764-1771.
5. Vierhapper H, Bieglmayer C, Heinze G & Baumgartner-Parzer S. Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 2004 14 580-583. (Pubitemid 39097078)
6. Schmid KW. Thyroid gland carcinoma. Praxis 1998 87 367-374.
7. Dralle H, Machens A & Lorenz K. Hereditary thyroid cancer. Chirurg 2008 79 1017-1028.
8. Osamura RY, Yasuda O, Kawakami T, Itoh Y, Inada K & Kakudo K. Immunoelectron microscopic demonstration of regulated pathway for calcitonin and constitutive pathway for carcinoembryonic antigen in the same cells of human medullary carcinomas of thyroid glands. Modern Pathology 1997 10 7-11. (Pubitemid 27090769)
9. Reubi JC, Schaer JC & Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Research 1997 57 1377-1386. (Pubitemid 27152565)
10. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hufner M, Niederle B & Brabant G. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Experimental and Clinical Endocrinology & Diabetes 2004 112 52-58.
11. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Vierhapper H & Niederle B. Recommendations for reporting C cell pathology of the thyroid. Wiener Klinische Wochenschrift 2002 114 274-278. (Pubitemid 34450420)
12. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M & Grunwald F. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009 19 327-332.
13. Vierhapper H, Niederle B, Bieglmayer C, Kaserer K & Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005 15 1267-1272. (Pubitemid 41821761)
14. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A & Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004 89 163-168. (Pubitemid 38183876)
15. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C, Fadda G, Baldini A, Carani C, Pontecorvi A & Roti E. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. Journal of Endocrinological Investigation 2006 29 427-437. (Pubitemid 44043359)
16. Mayr B, Brabant G & von zur Muhlen A. Incidental detection of familial medullary thyroid carcinoma by calcitonin screening for nodular thyroid disease. European Journal of Endocrinology 1999 141 286-289. (Pubitemid 29465935)
17. Lips CJ, Hoppener JW & Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Annals of Clinical Biochemistry 2001 38 168-179. (Pubitemid 32429998)
18. 18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Medica Austriaca 2003 30 22-25.
19. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL & Fombeur JP. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clinical Endocrinology 1995 42 453-460.
20. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M & Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2007 92 450-455. (Pubitemid 46255279)
21. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH & Chung JH. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001 11 73-80.
22. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E & Conte-Devolx B. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Journal of Clinical Endocrinology and Metabolism 1997 82 338-341. (Pubitemid 27068587)
23. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C & Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.World Journal of Surgery 2002 26 886-890.
24. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Practice & Research. Clinical Endocrinology & Metabolism 2008 22 941-953.
25. Hodak SP & Burman KD. The calcitonin conundrum - is it time for routine measurement of serum calcitonin in patients with thyroid nodules? Journal of Clinical Endocrinology and Metabolism 2004 89 511-514.
26. Dietlein M, Wieler H, Schmidt M, Schwab R, Goretzki PE & Schicha H. Routine measurement of serum calcitonin in patients with nodular thyroid disorders? Nuklearmedizin 2008 47 65-72.
27. Doyle P, Duren C, Nerlich K, Verburg FA, Grelle I, Jahn H, Fassnacht M, Mader U, Reiners C & Luster M. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. Journal of Clinical Endocrinology and Metabolism 2009 94 2970-2974.
28. Machens A, Hoffmann F, Sekulla C & Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocrine-Related Cancer 2009 16 1291-1298.
29. Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, Beck-Peccoz P & Fugazzola L. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocrine-Related Cancer 2007 14 393-403.
30. Scheuba C, Kaserer K, Kotzmann H, Bieglmayer C, Niederle B & Vierhapper H. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin. Thyroid 2000 10 413-416. (Pubitemid 30418746)
31. Sheu SY, Gorges R & Schmid KW. Hyperplasia of the thyroid gland. Pathology 2003 24 348-356.
32. Costante G, Durante C, Francis Z, Schlumberger M & Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nature Clinical Practice. Endocrinology & Metabolism 2009 5 35-44.
33. Ozgen AG, Hamulu F, Bayraktar F, Yilmaz C, Tuzun M, Yetkin E, Tuncyurek M & Kabalak T. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999 9 579-582. (Pubitemid 29296120)
34. Saad MF, Ordonez NG, Guido JJ & Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism 1984 59 850-856. (Pubitemid 14020683)
35. Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P & Modigliani E. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). Journal of Clinical Endocrinology and Metabolism 2000 85 919-922.